London, May 4, 2026, 15:03 BST
Halma plc is entering the shortened London week with shares not far off their 52-week peak. Friday’s jump—up 2.72% to £45.27—put the UK safety, environmental and healthcare tech group just 1.15% off its £45.80 high, even as the FTSE 100 edged down 0.14%.
Here’s why that’s important: with London markets closed Monday for the Early May Bank Holiday, Friday’s closing price is the last reference investors will have before they start eyeing Halma’s full-year results set for June 11. According to the London Stock Exchange calendar, May 4 is a non-trading day.
Halma has set expectations sky-high. Back in its March trading update, the company projected mid-teens organic constant-currency revenue growth—that is, growth excluding currency swings and the impact from acquisitions or disposals in their first year. Management is also targeting an adjusted EBIT margin near 22%. Adjusted EBIT reflects operating profit before interest, tax, and specific acquisition-related or other adjustments.
This latest shift came from the asset column. On April 30, Cardioline announced it had bought Cardios, a São Paulo firm producing Holter monitors and ambulatory blood-pressure devices, from Halma. Holter monitors track a patient’s heart rhythm continuously—longer than a clinic’s standard test. The companies left deal terms out. CEO Luis Meireles of Cardioline called it a “new geographic hub” for the group, while Cardios CEO Erica Chriguer pointed to the expanded range: Cardioline’s stress-test and ECG lines join Cardios’s offerings. Cardioline
Halma’s dealmaking streak continued April 13, when it announced the purchase of Surgistar, a California firm specializing in ophthalmic surgical tools. The move folds Surgistar into MicroSurgical Technology, expanding Halma’s healthcare unit. CEO Marc Ronchetti described cataract and ophthalmic surgery as “long term growth markets,” adding that Surgistar brings in more products for routine cataract procedures. Halma
Halma’s deal volume is running higher. Back in March, the group reported five completed acquisitions for the current financial year—three of those after Sept. 30—with a record £451 million deployed on a maximum total consideration basis. Order intake, Halma added, has continued to outpace both revenue for the year so far and the same stretch last year.
This rally outpaced recent action in a handful of UK engineering specialists. IMI slipped 2.01% and Renishaw edged up just 0.46% on May 1, according to Trading Economics, while Halma climbed 2.72%. The companies don’t compete directly, but investors often group them under the wider UK industrial tech umbrella for valuation comparisons.
There’s a wrinkle here. Shares have already climbed above Investing.com’s average 12-month analyst target of 4,032.6 pence—roughly 10.9% below the current price. Out of the same dataset: 8 analysts call it a buy, 8 say hold, and 2 recommend selling. The spread points to confidence in the company, but far less certainty on valuation.
Currency swings are another headache. Halma flagged that a stronger sterling versus the U.S. dollar and euro will likely shave roughly £63 million off reported 2026 revenue and around £14 million from profit, compared to 2025. It’s not a problem with operations, but it does take the shine off the top-line figures.
Halma presents a diverse package for investors to weigh. According to Reuters, the company works in Safety, Environmental & Analysis, and Healthcare, selling everything from fire and worker safety tech to water analysis tools, optoelectronics, and medical devices. That scope is a selling point—though it puts pressure on June’s results to prove growth isn’t just coming from a single strong segment.
